Biohaven Pharma (BHVN) Misses Q2 EPS by 172c
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.